Document Detail


Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma.
MedLine Citation:
PMID:  22534670     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The use of erlotinib throughout pregnancy has not been previously reported. We present the case of a 40 year-old female patient with stage IV lung adenocarcinoma, mediastinal, bone and cerebral metastasis, a EGFR mutation and no smoking history, who had begun first line treatment with erlotinib 150 mg once daily. After two and a half months of treatment a fourteen-week pregnancy was documented, and after informing on fetal risks secondary to erlotinib use and maternal risks secondary to treatment withholding, she decided to continue with treatment under clinical surveillance by both the oncology and obstetrics clinics. At thirty-three weeks gestation a live born 1600 g female was born by caesarean section without evidence of congenital malformations. Imaging assessment after eight months of treatment showed complete bone and central nervous system response and partial lung and mediastinal response. The patient is currently undergoing the 11th month of treatment and is asymptomatic, the baby is 4 months old and is in good health.
Authors:
Giovanna Rivas; Nestor Llinás; Carlos Bonilla; Juan Rubiano; Javier Cuello; Natalia Arango
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2012-04-24
Journal Detail:
Title:  Lung cancer (Amsterdam, Netherlands)     Volume:  77     ISSN:  1872-8332     ISO Abbreviation:  Lung Cancer     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-07-13     Completed Date:  2012-11-07     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  8800805     Medline TA:  Lung Cancer     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  469-72     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
Affiliation:
Clinical Oncology Group, Cancerology National Institute, E.S.E., Bogota, Colombia. govariv@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / diagnosis,  drug therapy*,  genetics
Adult
Antineoplastic Agents / therapeutic use*
Base Sequence
Female
Humans
Lung Neoplasms / diagnosis,  drug therapy*,  genetics
Mutation
Neoplasm Metastasis
Pregnancy
Pregnancy Complications, Neoplastic / diagnosis,  drug therapy*
Pregnancy Outcome
Protein Kinase Inhibitors / therapeutic use*
Quinazolines / therapeutic use*
Receptor, Epidermal Growth Factor / antagonists & inhibitors,  genetics
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Protein Kinase Inhibitors; 0/Quinazolines; EC 2.7.10.1/Receptor, Epidermal Growth Factor; J4T82NDH7E/erlotinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially b...
Next Document:  External Ophthalmoplegia Associated With Hashimoto's Thyroiditis and Recovered on Corticosteroid Tre...